Blanco-Guillot Francles, Delgado-Sánchez Guadalupe, Mongua-Rodríguez Norma, Cruz-Hervert Pablo, Ferreyra-Reyes Leticia, Ferreira-Guerrero Elizabeth, Yanes-Lane Mercedes, Montero-Campos Rogelio, Bobadilla-Del-Valle Miriam, Torres-González Pedro, Ponce-de-León Alfredo, Sifuentes-Osornio José, Garcia-Garcia Lourdes
Doctorado en Ciencias en Enfermedades Infecciosas, Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
PLoS One. 2017 Sep 13;12(9):e0184675. doi: 10.1371/journal.pone.0184675. eCollection 2017.
Many studies have explored the relationship between diabetes mellitus (DM) and tuberculosis (TB) demonstrating increased risk of TB among patients with DM and poor prognosis of patients suffering from the association of DM/TB. Owing to a paucity of studies addressing this question, it remains unclear whether patients with DM and TB are more likely than TB patients without DM to be grouped into molecular clusters defined according to the genotype of the infecting Mycobacterium tuberculosis bacillus. That is, whether there is convincing molecular epidemiological evidence for TB transmission among DM patients. Objective: We performed a systematic review and meta-analysis to quantitatively evaluate the propensity for patients with DM and pulmonary TB (PTB) to cluster according to the genotype of the infecting M. tuberculosis bacillus.
We conducted a systematic search in MEDLINE and LILACS from 1990 to June, 2016 with the following combinations of key words "tuberculosis AND transmission" OR "tuberculosis diabetes mellitus" OR "Mycobacterium tuberculosis molecular epidemiology" OR "RFLP-IS6110" OR "Spoligotyping" OR "MIRU-VNTR". Studies were included if they met the following criteria: (i) studies based on populations from defined geographical areas; (ii) use of genotyping by IS6110- restriction fragment length polymorphism (RFLP) analysis and spoligotyping or mycobacterial interspersed repetitive unit-variable number of tandem repeats (MIRU-VNTR) or other amplification methods to identify molecular clustering; (iii) genotyping and analysis of 50 or more cases of PTB; (iv) study duration of 11 months or more; (v) identification of quantitative risk factors for molecular clustering including DM; (vi) > 60% coverage of the study population; and (vii) patients with PTB confirmed bacteriologically. The exclusion criteria were: (i) Extrapulmonary TB; (ii) TB caused by nontuberculous mycobacteria; (iii) patients with PTB and HIV; (iv) pediatric PTB patients; (v) TB in closed environments (e.g. prisons, elderly homes, etc.); (vi) diabetes insipidus and (vii) outbreak reports. Hartung-Knapp-Sidik-Jonkman method was used to estimate the odds ratio (OR) of the association between DM with molecular clustering of cases with TB. In order to evaluate the degree of heterogeneity a statistical Q test was done. The publication bias was examined with Begg and Egger tests. Review Manager 5.3.5 CMA v.3 and Biostat and Software package R were used.
Selection criteria were met by six articles which included 4076 patients with PTB of which 13% had DM. Twenty seven percent of the cases were clustered. The majority of cases (48%) were reported in a study in China with 31% clustering. The highest incidence of TB occurred in two studies from China. The global OR for molecular clustering was 0.84 (IC 95% 0.40-1.72). The heterogeneity between studies was moderate (I2 = 55%, p = 0.05), although there was no publication bias (Beggs test p = 0.353 and Eggers p = 0.429).
There were very few studies meeting our selection criteria. The wide confidence interval indicates that there is not enough evidence to draw conclusions about the association. Clustering of patients with DM in TB transmission chains should be investigated in areas where both diseases are prevalent and focus on specific contexts.
许多研究探讨了糖尿病(DM)与结核病(TB)之间的关系,结果表明糖尿病患者患结核病的风险增加,且糖尿病/结核病患者的预后较差。由于针对这一问题的研究较少,目前尚不清楚糖尿病合并结核病患者是否比未患糖尿病的结核病患者更有可能被归类为根据感染结核分枝杆菌基因型定义的分子簇。也就是说,是否有令人信服的分子流行病学证据表明糖尿病患者之间存在结核传播。目的:我们进行了一项系统评价和荟萃分析,以定量评估糖尿病合并肺结核(PTB)患者根据感染结核分枝杆菌基因型聚类的倾向。
我们在1990年至2016年6月期间对MEDLINE和LILACS进行了系统检索,使用了以下关键词组合:“结核病与传播”或“结核病与糖尿病”或“结核分枝杆菌分子流行病学”或“RFLP-IS6110”或“Spoligotyping”或“MIRU-VNTR”。符合以下标准的研究纳入分析:(i)基于特定地理区域人群的研究;(ii)使用IS6110限制性片段长度多态性(RFLP)分析、Spoligotyping或分枝杆菌插入重复单位可变数目串联重复序列(MIRU-VNTR)或其他扩增方法进行基因分型以识别分子簇;(iii)对50例或更多例肺结核病例进行基因分型和分析;(iv)研究持续时间为11个月或更长;(v)确定分子簇的定量危险因素,包括糖尿病;(vi)研究人群覆盖率>60%;(vii)痰菌阳性的肺结核患者。排除标准为:(i)肺外结核;(ii)非结核分枝杆菌引起的结核病;(iii)肺结核合并艾滋病患者;(iv)儿童肺结核患者;(v)封闭环境(如监狱、养老院等)中的结核病;(vi)尿崩症;(vii)暴发报告。采用Hartung-Knapp-Sidik-Jonkman方法估计糖尿病与结核病病例分子簇之间关联的比值比(OR)。为了评估异质性程度,进行了统计学Q检验。采用Begg检验和Egger检验检查发表偏倚。使用Review Manager 5.3.5 CMA v.3以及Biostat和软件包R进行分析。
6篇文章符合纳入标准,共纳入4076例肺结核患者,其中13%患有糖尿病。27%的病例为聚集性病例。大多数病例(48%)来自中国的一项研究,其中31%为聚集性病例。结核病发病率最高的两项研究来自中国。分子簇的总体OR为0.84(95%CI 0.40-1.72)。研究间的异质性为中度(I2 = 55%,p = 0.05),尽管不存在发表偏倚(Begg检验p = 0.353,Egger检验p = 0.429)。
符合我们纳入标准的研究很少。较宽的置信区间表明没有足够的证据得出关于两者关联的结论。在两种疾病均流行的地区,应针对结核病传播链中糖尿病患者的聚集情况进行调查,并关注特定背景。